JAZZ (Jazz Pharmaceuticals) Cyclically Adjusted Revenue per Share: $53.61 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JAZZ Jazz Pharmaceuticals PLC JAZZ
73 GF Score
Price $252.86
GF Value $150.39
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share?

Jazz Pharmaceuticals JAZZ -2.19% 73 Cyclically Adjusted Revenue per Share is $53.61 as of Mar. 2026. GuruFocus rates JAZZ with a GF Score™ of 73/100 and a GF Value™ of $150.39 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was $16.171. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $53.61 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Jazz Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 13.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 17.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 20.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Jazz Pharmaceuticals was 24.10% per year. The lowest was 12.80% per year. And the median was 21.80% per year.

As of today (2026-08-01), Jazz Pharmaceuticals's current stock price is $252.86. Jazz Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $53.61. Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 4.72.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jazz Pharmaceuticals was 15.25. The lowest was 2.06. And the median was 5.31.


Jazz Pharmaceuticals  (NAS:JAZZ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=252.86/53.61
=4.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jazz Pharmaceuticals was 15.25. The lowest was 2.06. And the median was 5.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.93 36.13 41.46 46.18 51.83

Jazz Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.41 48.89 50.17 51.83 53.61

JAZZ vs BBIO, ASND, EXEL: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


JAZZ
73GF Score
Jazz Pharmaceuticals PLC JAZZ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jazz Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=16.171/127.8300*127.8300
=16.171

Current CPI (Mar. 2026) = 127.8300.

Jazz Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 6.143 101.072 7.769
201609 6.055 100.274 7.719
201612 6.499 99.676 8.335
201703 6.147 100.374 7.828
201706 6.417 100.673 8.148
201709 6.704 100.474 8.529
201712 7.132 100.075 9.110
201803 7.268 100.573 9.238
201806 8.146 101.072 10.303
201809 7.588 101.371 9.569
201812 7.888 100.773 10.006
201903 8.750 101.670 11.001
201906 9.301 102.168 11.637
201909 9.361 102.268 11.701
201912 10.160 102.068 12.724
202003 9.556 102.367 11.933
202006 10.068 101.769 12.646
202009 10.685 101.072 13.514
202012 11.640 101.072 14.722
202103 10.405 102.367 12.993
202106 12.647 103.364 15.640
202109 13.676 104.859 16.672
202112 14.575 106.653 17.469
202203 12.935 109.245 15.136
202206 14.707 112.779 16.670
202209 14.982 113.504 16.873
202212 15.416 115.436 17.071
202303 12.102 117.609 13.154
202306 13.018 119.662 13.907
202309 13.636 120.749 14.436
202312 14.526 120.749 15.378
202403 14.423 120.990 15.238
202406 14.705 122.318 15.368
202409 16.699 121.594 17.555
202412 17.695 122.439 18.474
202503 14.718 123.405 15.246
202506 17.088 124.492 17.546
202509 18.279 124.810 18.721
202512 19.619 125.770 19.940
202603 16.171 127.830 16.171

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $53.61 mean?
Jazz Pharmaceuticals (JAZZ) has a Cyclically Adjusted Revenue per Share of $53.61 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Jazz Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $53.61. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to BBIO and ASND?
Jazz Pharmaceuticals' Cyclically Adjusted Revenue per Share of $53.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $53.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $150.39, compared to a current price of $252.86 — trading 68.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $53.61. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current Cyclically Adjusted Revenue per Share is $53.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of $252.86 is trading 68.1% above its estimated GF Value™ of $150.39. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for JAZZ:

  • Cyclically Adjusted Revenue per Share: $53.61
  • GF Value™: $150.39 vs. price of $252.86 (68.1% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for JAZZ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$252.86
Price
$150.39
GF Value